Novacyt

Novacyt EBIT Growth

The Year-over-Year EBIT Growth of Novacyt (ALNOV.PA) as of Sep 17, 2026 is -5.16 %. In the previous year, Year-over-Year EBIT Growth was -0.09 % — a change of 5,969.84% (lower).

EBIT Growth

-5.16 %

YoY

5,969.84%

Last updated:

Year-over-Year EBIT Growth of Novacyt is 2026 -5.16 % . Year-over-Year EBIT Growth of Novacyt was 2025 -0.09 % . It decreases by 5,969.84% lower compared to the previous year.

The Novacyt EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2017
51.13 GBP
Jan 1, 2018
48.93 GBP
Jan 1, 2019
-38.55 GBP
Jan 1, 2020
14,954.76 GBP
Jan 1, 2021
-99.28 GBP
Jan 1, 2022
-1,217.91 GBP
Jan 1, 2023
-0.09 GBP
Jan 1, 2024
-5.16 GBP
The Novacyt EBIT Growth history
YEAREBIT GrowthYoY
-5.16 %+5,969.84%
-0.09 %-99.99%
-1,217.91 %+1,126.77%
-99.28 %-100.66%
14,954.76 %-38,894.63%
-38.55 %-178.78%
48.93 %-4.29%
51.13 %-1,985.07%
-2.71 %-132.15%
8.43 %
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Year-over-Year EBIT Growth of Novacyt is -5.16 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Novacyt since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Novacyt historically and in real time.

Access this data via the Eulerpool API

Growth — Novacyt

All Key Metrics — Novacyt